US equity indexes rose after midday Wednesday after the Treasury Department said it would increase buybacks of long-dated government debt to at least $4 billion per operation in September from $2 billion, and President Donald Trump paused tariffs on certain Canadian goods in a late Tuesday Truth Social post.
The Nasdaq Composite rose 0.2% to 26,343.5, and the S&P 500 gained 0.3% to 7,716.1. The Dow Jones Industrial Average increased 0.2% to 53,456.1. Health and materials led the gainers, while technology and industrials led the decliners.
The yield on 30-year Treasuries fell 7 basis points to 5.215%, while the 10-year yield fell 3 basis points to 4.677%.
Trump also said the proposed Keystone XL Pipeline, which was canceled in 2021, may be revived. The tariff play comes ahead of negotiations for the US-Mexico-Canada Trade Agreement.
Gold futures gained 3% to $4,553.5 per ounce, and silver futures rose 3% to $65.95.
In economic news, US crude oil stocks, including those in the Strategic Petroleum Reserve, fell by 900,000 barrels in the week ended Aug. 14, following an increase of 11.3 million barrels in the prior week.
Excluding SPR inventories, commercial crude oil stocks rose by 4.4 million barrels compared with a 17.4-million-barrel gain in the week prior, and the 200,000-barrel increase expected in a survey compiled by Bloomberg.
The US West Texas Intermediate crude oil contract rose 2.4% to $86.99 per barrel.
US mortgage applications fell by 0.4% in the week ended Aug. 14, with an increase in refinancing activity offset by declining home purchase applications, according to the Mortgage Bankers Association.
"In addition to the economic uncertainty, affordability difficulties have reemerged as a reason for homebuyers to delay purchase decisions given the impact of higher mortgage rates on monthly mortgage payments," said MBA deputy chief economist Joel Kan.
In company news, Moderna (MRNA) shares climbed 150%, and Merck (MRK) shares gained 11.5% after the companies said a trial of intismeran autogene combined with Keytruda met the primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma.
Target (TGT) shares rose 5.8% after the company posted higher-than-expected fiscal Q2 results and boosted its 2026 guidance. The company reported fiscal Q2 adjusted earnings of $4.11 per diluted share, up from $2.05 a year earlier and above FactSet consensus of $2.34. Fiscal Q2 net sales were $26.54 billion, up from $25.21 billion a year ago and above the FactSet consensus of $26.13 billion. For fiscal 2026, the company lifted its adjusted EPS guidance to between $9.90 and $10.90 from $7.50 to $8.50 earlier, compared with FactSet estimates of $8.52.